Citigroup Initiates SAB Biotherapeutics at Buy With $11 Price Target
SAB Biotherapeutics (SABS) has an average rating of buy and mean price target of $10.30, according to analysts polled by FactSet.(covers equity, commodity and economic research from major banks and research firms in North America, Asia and Europe. Research providers may contact us here: https://www..com/contact-us)